Big Data Science in Medicine

Big Data Science in Medicine Big Data promises to revolutionise medicine. We bring together leading lights of big data research a

When cutting edge biomedical research meets state-of-the-art big data technologies, the extraordinary seems possible. At the forefront of scientific innovation is the recognition that the diseases of ageing are not inevitable facts of life; instead they are biological challenges with real solutions. Big-data can help us gain key insights into the biological process of aging and accelerate medicine to bring health and longevity to all. At the Big Data Science in Medicine meeting we bring together leading lights from artificial intelligence, biomedical science and regenerative medicine for an evening of talks and discussion in Oxford with the ambition of accelerating research in longevity.

New paper demonstrating intestinal barrier repair function in multiple preclinical models by a novel PHD1/2 inhibitor de...
12/12/2024

New paper demonstrating intestinal barrier repair function in multiple preclinical models by a novel PHD1/2 inhibitor designed using generative AI to be gut restricted.

Generative artificial intelligence is used to design an effective treatment for inflammatory bowel disease in preclinical models.

New important paper in AI-powered drug discovery and aging research with experimental validation:
08/03/2024

New important paper in AI-powered drug discovery and aging research with experimental validation:

An AI-generated small-molecule inhibitor treats fibrosis in vivo and in phase I clinical trials.

17/08/2023
Consumer-level Generative AI in medicine should be regulated.You probably expected me to be the last person to say this ...
08/02/2023

Consumer-level Generative AI in medicine should be regulated.

You probably expected me to be the last person to say this since we started presenting on GANs in 2015 and publishing in generative AI since 2016. But when you make generative AI for internal use or B2B applications, the resulting products will need to go through rigorous validation before these products reach the clinic. And businesses will make every effort to validate.
Consumers may self-medicate. And to allow for this, in the short term, we need benchmarking tools, large GPT-friendly biomedical training sets, and some warnings and some level of regulation in the short term.
Once you get addicted to conversational generative AI, you are very likely to trust the systems. And they are very likely to self-medicate.

Here is a brief article outlining these points.

Generative artificial intelligence tools such as chatGPT have many uses in medicine, but a lack of accuracy poses problems.

Please check out the interview with Joan Mannick, who co-founded resTORbio, and is now heading R&D at David Sinclair's a...
14/06/2021

Please check out the interview with Joan Mannick, who co-founded resTORbio, and is now heading R&D at David Sinclair's and Nir Barzilai's Life Biosciences. You can see all of them at the 8th Aging Research and Drug Discovery.

In 2014 ResTORbio spun off out of Novartis and went public to try a longevity drug as a vaccine-potentiating agent in the elderly. The company was led by Dr. Joan Mannick, a physician with deep interest in aging. The trial failed in Phase III providing valuable experience, and her work continues.

A new paper on AI in Longevity Medicine
18/01/2021

A new paper on AI in Longevity Medicine

Recent advances in deep learning enabled the development of AI systems that outperform humans in many tasks and have started to empower scientists and physicians with new tools. In this Comment, we discuss how recent applications of AI to aging research are leading to the emergence of the field of l...

In September we are launching our full-service AI-powered target discovery platform for industry and academics. You will...
02/07/2020

In September we are launching our full-service AI-powered target discovery platform for industry and academics. You will be able to start unicorn businesses, publish top-tier academic papers, and help solve diseases using your own data, or using the data on the platform. We encourage you to try it out and sign up as a launch partner.

It natively integrates into the upcoming generative chemistry suite that we will open to the maximum of 5 big pharma companies this year.

Our goal is to democratize pharmaceutical R&D, help biologists think like drug hunters, and enable them to produce impactful results.

We are excited to announce that InSilico Medicine will be soon releasing its most advanced OMICs data interpretation and Target ID platform called that is designed to bring a new visual experience to biologists.

Although the official release is planned for September, those interested can get a first glimpse of the product even now.

Please visit https://insilico.com/pandomics

Let us know your thoughts and tell us about the features you would like to see. Any feedback will be very much appreciated!

You can reach us at: pandomics@insilico.com

Alex Zhavoronkov Alexander Aliper Alexey Dubovenko Jan Szollos Ivan Ozerov Regina Lin Jimmy Yen Chu Lin Ola Popova Polina Firsanova

The new Nature Biotech Paper: Deep learning enables rapid identification of potent DDR1 kinase inhibitors
04/09/2019

The new Nature Biotech Paper: Deep learning enables rapid identification of potent DDR1 kinase inhibitors

A machine learning model allows the identification of new small-molecule kinase inhibitors in days.

08/12/2018

Time to revive the B**M series?

Address

Oxford
OX11HP

Alerts

Be the first to know and let us send you an email when Big Data Science in Medicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Big Data Science in Medicine:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram